Related Articles for PubMed (Select 17222348)

Interferon alpha therapy for hepatitis C: treatment completion and response rates among patients with substance use disorders.

Huckans MS, Loftis JM, Blackwell AD, Linke A, Hauser P.

Subst Abuse Treat Prev Policy. 2007 Jan 12;2:4.

PMID: 17222348 [PubMed]

Related Articles Free article in PMC

Daily interferon induction regimen using different manufactured interferons (alpha-2A or alpha-2B) in combination with ribavirin for treatment of chronic hepatitis C: a prospective randomized study.

Braga EL, Lyra AC, Nascimento L, Netto E, Kalabrik L, Lyra LG.

Arq Gastroenterol. 2006 Oct-Dec;43(4):275-9.

PMID: 17406754 [PubMed - indexed for MEDLINE]

Hepatitis C testing and infection rates in bipolar patients with and without comorbid substance use disorders.

Matthews AM, Huckans MS, Blackwell AD, Hauser P.

Bipolar Disord. 2008 Mar;10(2):266-70.

PMID: 18271905 [PubMed - indexed for MEDLINE]

Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.

Yamada G, Iino S, Okuno T, Omata M, Kiyosawa K, Kumada H, Hayashi N, Sakai T.

Clin Drug Investig. 2008;28(1):9-16. Erratum in: Clin Drug Investig. 2008;28(4):210.

PMID: 18081356 [PubMed - indexed for MEDLINE]

Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial.

Liu CH, Liu CJ, Lin CL, Liang CC, Hsu SJ, Yang SS, Hsu CS, Tseng TC, Wang CC, Lai MY, Chen JH, Chen PJ, Chen DS, Kao JH.

Clin Infect Dis. 2008 Nov 15;47(10):1260-9.

PMID: 18834319 [PubMed - indexed for MEDLINE]

Integrated hepatitis C virus treatment: addressing comorbid substance use disorders and HIV infection.

Huckans MS, Blackwell AD, Harms TA, Indest DW, Hauser P.

AIDS. 2005 Oct;19 Suppl 3:S106-15.

PMID: 16251805 [PubMed - indexed for MEDLINE]

Psychiatric comorbidity does not predict interferon treatment completion rates in hepatitis C seropositive veterans.

Dollarhide AW, Loh C, Leckband SG, Endow-Eyer R, Robinson S, Meyer JM.

J Clin Gastroenterol. 2007 Mar;41(3):322-8.

PMID: 17426475 [PubMed - indexed for MEDLINE]

Antiviral Therapy Completion and Response Rates Among Hepatitis C Patients With and Without Schizophrenia.

Huckans M, Mitchell A, Ruimy S, Loftis J, Hauser P.

Schizophr Bull. 2008 Jun 17. [Epub ahead of print]

PMID: 18562341 [PubMed - as supplied by publisher]

Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.

Escudero A, Rodríguez F, Serra MA, Del Olmo JA, Montes F, Rodrigo JM.

J Gastroenterol Hepatol. 2008 Jun;23(6):861-6. Epub 2008 Apr 19.

PMID: 18422960 [PubMed - indexed for MEDLINE]

10:

Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.

Yu JW, Wang GQ, Sun LJ, Li XG, Li SC.

J Gastroenterol Hepatol. 2007 Jun;22(6):832-6.

PMID: 17565637 [PubMed - indexed for MEDLINE]

11:

Interferon beta 1a versus interferon beta 1a plus ribavirin for the treatment of chronic hepatitis C in Chinese patients: a randomized, placebo-controlled trial.

Han Q, Liu Z, Kang W, Li H, Zhang L, Zhang N.

Dig Dis Sci. 2008 Aug;53(8):2238-45. Epub 2007 Dec 13.

PMID: 18080763 [PubMed - indexed for MEDLINE]

12:

Early discontinuation of ribavirin in HCV-2 and HCV-3 patients responding to Peg-interferon alpha-2a and ribavirin.

Andriulli A, Cursaro C, Cozzolongo R, Iacobellis A, Valvano MR, Mangia A, Minerva N, Bacca D, Stanzione M, Scuteri A, Montalto G, Andreone P.

J Viral Hepat. 2008 Aug 28. [Epub ahead of print]

PMID: 18761603 [PubMed - as supplied by publisher]

13:

[Efficacy of pegylated interferon alpha-2a and ribavirin treatment in chronic hepatitis C patients depends on various baseline parameters and early viral kinetics]

Husa P, Slesinger P, Stroblová H, Svobodník A, Husová L.

Klin Mikrobiol Infekc Lek. 2008 Apr;14(2):67-73. Czech.

PMID: 18756436 [PubMed - indexed for MEDLINE]

14:

Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen.

Crespo M, Mira JA, Pineda JA, Van den Eynde E, Ríos-Villegas MJ, Collado A, Girón-González JA, López-Cortés LF, González-Serrano M, Rivero A, Merino D, Esteban JI.

J Antimicrob Chemother. 2008 Oct;62(4):793-6. Epub 2008 Jun 21.

PMID: 18567911 [PubMed - indexed for MEDLINE]

15:

Induction versus noninduction antiviral therapy for chronic hepatitis C virus in patients with congenital coagulation disorders: a Canadian multicentre trial.

Chatterjee A, Swain MG, Lee SS, Bain VG, Peltekian K, Croitoru K, Adams PC, Kaita K, Teitel J, Heathcote EJ.

Can J Gastroenterol. 2007 Feb;21(2):91-5.

PMID: 17299612 [PubMed - indexed for MEDLINE]

16:

[Comparison of therapeutic results between combination therapy of peginterferon alpha-2a plus ribavirin and interferon alpha-2b plus ribavirin according to treatment duration in patients with chronic hepatitis C]

Lee HJ, Eun JR, Choi JW, Kim KO, Moon HJ.

Korean J Hepatol. 2008 Mar;14(1):46-57. Korean.

PMID: 18367857 [PubMed - indexed for MEDLINE]

17:

The response to pegylated interferon alpha 2a in haemodialysis patients with hepatitis C virus infection.

Akhan SC, Kalender B, Ruzgar M.

Infection. 2008 Aug;36(4):341-4. Epub 2008 Jul 15.

PMID: 18629437 [PubMed - indexed for MEDLINE]

18:

Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b.

Vispo E, Barreiro P, Rodriguez-Nóvoa S, Morello J, Labarga P, Martín-Carbonero L, Maida I, García-Gascó P, Soriano V.

Antivir Ther. 2008;13(4):511-7.

PMID: 18672529 [PubMed - indexed for MEDLINE]

19:

Occult HBV infection may represent a major risk factor of non-response to antiviral therapy of chronic hepatitis C.

Mrani S, Chemin I, Menouar K, Guillaud O, Pradat P, Borghi G, Trabaud MA, Chevallier P, Chevallier M, Zoulim F, Trépo C.

J Med Virol. 2007 Aug;79(8):1075-81.

PMID: 17596829 [PubMed - indexed for MEDLINE]

20:

Role of rapid virological response in prediction of sustained virological response to Peg-IFN plus ribavirin in HCV / HIV co-infected individuals.

Shea DO, Tuite H, Farrell G, Codd M, Mulcahy F, Norris S, Bergin C.

J Viral Hepat. 2008 Jul;15(7):482-9. Epub 2008 Jan 23.

PMID: 18221297 [PubMed - indexed for MEDLINE]

Recent Activity